Eli Lilly and Company (LLY) Shares Bought by Monetary Management Group Inc.
Monetary Management Group Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,535 shares of the company’s stock after acquiring an additional 675 shares during the quarter. Monetary Management Group Inc.’s holdings in Eli Lilly and were worth $1,443,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pathstone Family Office LLC increased its stake in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new position in shares of Eli Lilly and during the second quarter valued at approximately $494,000. Acrospire Investment Management LLC increased its stake in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. San Francisco Sentry Investment Group CA acquired a new position in shares of Eli Lilly and during the second quarter valued at approximately $129,000. Finally, Point72 Asia Hong Kong Ltd grew its position in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. Institutional investors and hedge funds own 76.61% of the company’s stock.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The disclosure for this sale can be found here. Insiders have sold a total of 772,003 shares of company stock valued at $64,837,441 in the last three months. Company insiders own 0.20% of the company’s stock.
LLY has been the topic of several recent research reports. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies restated a “buy” rating and issued a $103.00 price target on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research report on Thursday, October 26th. Jefferies Group LLC restated a “buy” rating and issued a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and an average target price of $89.97.
Shares of Eli Lilly and Company (LLY) opened at $83.68 on Thursday. The stock has a market cap of $91,919.42, a price-to-earnings ratio of 20.41, a price-to-earnings-growth ratio of 1.84 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the business posted $0.88 EPS. equities research analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Shares Bought by Monetary Management Group Inc.” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/23/eli-lilly-and-company-lly-shares-bought-by-monetary-management-group-inc.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.